Dificid (fidaxomicin) is a brand-name drug prescribed for diarrhea caused by Clostridioides difficile (C. diff). It’s available as an oral tablet and oral liquid suspension. The cost of Dificid with ...
Dificid (fidaxomicin) is prescribed to treat diarrhea from Clostridioides difficile bacteria. Dificid’s cost may depend on your dosage and whether you have health insurance. It also may depend on the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The U.S. Food and Drug Administration has approved Dificid tablets for the treatment of Clostridium difficile-associated diarrhea, according to an FDA news release. The safety and efficacy of Dificid ...
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug ...
Optimer said that preliminary gross product sales of its only marketed product, Dificid (fidaxomicin), were $74.4 million in the US and Canada for the full year 2012 compared to $24.4 million in 2011.
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Therapeutic Goods Administration, the Australian regulatory body for therapeutic goods such as medicines, has approved DIFICID® ...
TORONTO, July 5, 2012 /CNW/ - Optimer Pharmaceuticals Canada, Inc. announced today the approval of DIFICID (fidaxomicin) by Health Canada for the treatment of Clostridium difficile infection (CDI) in ...
The U.S. Food and Drug Administration approved Merck's (MRK-0.29%) Dificid drug for children aged 6 months and older who have diarrhea caused by a specific bacterial infection called Clostridioides ...
SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for diarrhea caused by a bacterial infection. The agency announced the approval of Optimer Pharmaceuticals’ Dificid ...
NEW YORK -- Shares of Optimer Pharmaceuticals tumbled 6 percent Tuesday as Wall Street weighed in on the company's marketing strategy and sales of its antibacterial drug Dificid. THE SPARK: Optimer ...
Merck & Co., Inc. MRK announced that the FDA has granted approval to its new drug application ("NDA") and a supplemental NDA (sNDA) for its antibacterial medicine Dificid (fidaxomicin). The NDA sought ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results